Hologic, Inc. $HOLX Shares Sold by IQ EQ FUND MANAGEMENT IRELAND Ltd

IQ EQ FUND MANAGEMENT IRELAND Ltd lessened its stake in Hologic, Inc. (NASDAQ:HOLX) by 3.0% during the second quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 29,797 shares of the medical equipment provider’s stock after selling 922 shares during the quarter. IQ EQ FUND MANAGEMENT IRELAND Ltd’s holdings in Hologic were worth $1,942,000 at the end of the most recent quarter.

A number of other hedge funds also recently made changes to their positions in HOLX. Chung Wu Investment Group LLC acquired a new position in shares of Hologic during the 2nd quarter valued at $26,000. Caitong International Asset Management Co. Ltd lifted its holdings in shares of Hologic by 193.6% during the 2nd quarter. Caitong International Asset Management Co. Ltd now owns 414 shares of the medical equipment provider’s stock valued at $27,000 after acquiring an additional 273 shares in the last quarter. Zions Bancorporation National Association UT acquired a new position in shares of Hologic during the 1st quarter valued at $34,000. Cromwell Holdings LLC lifted its holdings in shares of Hologic by 307.0% during the 2nd quarter. Cromwell Holdings LLC now owns 578 shares of the medical equipment provider’s stock valued at $38,000 after acquiring an additional 436 shares in the last quarter. Finally, Allworth Financial LP lifted its holdings in shares of Hologic by 46.0% during the 1st quarter. Allworth Financial LP now owns 686 shares of the medical equipment provider’s stock valued at $40,000 after acquiring an additional 216 shares in the last quarter. Institutional investors and hedge funds own 94.73% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities analysts recently weighed in on the stock. Morgan Stanley lifted their target price on shares of Hologic from $65.00 to $69.00 and gave the company an “equal weight” rating in a report on Thursday, July 31st. Stephens lowered shares of Hologic from an “overweight” rating to an “equal weight” rating and reduced their target price for the company from $78.00 to $76.00 in a report on Wednesday, October 22nd. Mizuho lowered shares of Hologic from an “outperform” rating to a “neutral” rating and lifted their target price for the company from $70.00 to $78.00 in a report on Thursday, October 23rd. Raymond James Financial lowered shares of Hologic from a “moderate buy” rating to a “hold” rating in a report on Wednesday, October 22nd. Finally, UBS Group boosted their price objective on shares of Hologic from $65.00 to $70.00 and gave the stock a “neutral” rating in a report on Thursday, July 31st. One research analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating and thirteen have assigned a Hold rating to the company’s stock. Based on data from MarketBeat, the company has an average rating of “Hold” and an average price target of $79.23.

Insider Activity

In related news, Director Christiana Stamoulis sold 7,402 shares of the stock in a transaction dated Monday, October 20th. The shares were sold at an average price of $73.07, for a total transaction of $540,864.14. Following the sale, the director owned 47,336 shares in the company, valued at $3,458,841.52. This represents a 13.52% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CEO Stephen P. Macmillan sold 138,358 shares of the stock in a transaction dated Monday, September 22nd. The stock was sold at an average price of $66.97, for a total transaction of $9,265,835.26. Following the sale, the chief executive officer owned 1,234,624 shares in the company, valued at approximately $82,682,769.28. This trade represents a 10.08% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. 1.88% of the stock is owned by corporate insiders.

Hologic Price Performance

HOLX opened at $74.01 on Wednesday. The firm has a market cap of $16.46 billion, a price-to-earnings ratio of 30.71, a price-to-earnings-growth ratio of 2.54 and a beta of 0.63. Hologic, Inc. has a fifty-two week low of $51.90 and a fifty-two week high of $84.39. The company’s 50-day moving average price is $67.91 and its 200 day moving average price is $64.25. The company has a quick ratio of 2.81, a current ratio of 3.55 and a debt-to-equity ratio of 0.52.

Hologic (NASDAQ:HOLX) last released its quarterly earnings data on Wednesday, July 30th. The medical equipment provider reported $1.08 earnings per share for the quarter, topping the consensus estimate of $1.05 by $0.03. The firm had revenue of $1.02 billion for the quarter, compared to analyst estimates of $1.01 billion. Hologic had a net margin of 13.79% and a return on equity of 19.69%. Hologic’s quarterly revenue was up 1.2% on a year-over-year basis. During the same quarter in the prior year, the business earned $1.06 earnings per share. As a group, sell-side analysts expect that Hologic, Inc. will post 4.28 earnings per share for the current year.

Hologic Company Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.